Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
June 2, 2022
Chinook Therapeutics (KDNY) public offering of 6,4 M shares priced at $14.00 raising $105 M
June 2, 2022
RegMed Investors (RMi) - Q1/22 Cell and Gene Therapy Earnings Scorecard Results
May 3, 2022
RegMed Investors: The week that will define the cell and gene therapy sector’s share pricing month
April 28, 2022
The Biostage (BSTG) Chronicles: Surgeon on trial in Sweden over experimental windpipe transplants
April 28, 2022
Alnylam Pharmaceuticals (ALNY) reports Q1/2022 earnings; net loss and net product revenue and collaboration decreases
March 22, 2022
Applied Genetic Technology (AGTC) prices 7.5 M share public offering
March 4, 2022
UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies
February 17, 2022
The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW)
January 11, 2022
The Biostage Chronicles: dispose and disregard, fit for the barrel
December 4, 2021
RegMed Investors (RMi): The week in review …
November 9, 2021
Chinook Therapeutics (KDNY) prices an upsized offering at $14.00 per share
October 30, 2021
The Biostage (BSTG) Chronicles: what’s there to invest in?
September 23, 2021
Q2/21 Earnings - (LPS - loss-per-share) Results
September 17, 2021
The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?
August 20, 2021
The Biostage (BSTG) Chronicles: Facts from filed 10-Q
August 13, 2021
The Biostage (BSTG) Chronicles - notice how the shares trade with and without being “pumped/promoted”?
July 22, 2021
The Biostage (BSTG) Chronicles – a number of questions have been asked and never answered
July 3, 2021
Intellia Therapeutics (NTLA) closes 4.758 M shares offering priced at $145.00 per share
June 23, 2021
The Biostage (BSTG) Chronicles: the annual meeting on Thursday 6/24/21, will there be any answers?
May 21, 2021
Biostage (BSTG) Chronicles: Another Q reporting MISS, why another missed date filing?
April 21, 2021
The Biostage (BSTG) Chronicles: post 10-K filing, too many questions remain unanswered
April 13, 2021
The Biostage (BSTG) Chronicles: Questions continue without any responses
April 7, 2021
The Biostage (BSTG) Chronicles: Questions continue without any answers to date
April 7, 2021
Homology Medicines (FIXX) prices $50 million offering at $7.90
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.